Fig. 3From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790MBest changes from baseline in tumor-size since treatment of first-generation EGFR TKIs in the cohorts of EGFR 19delins (A) and EGFR 19del (B)Back to article page